- Home
- PCRX vs CHY Comparison
PCRX vs CHY Comparison
Compare PCRX & CHY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PCRX | CHY |
|---|---|---|
| Founded | 2006 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 896.9M |
| IPO Year | 2010 | N/A |
Fundamental Metrics
Financial Performance| Metric | PCRX | CHY |
|---|---|---|
| Price | $23.21 | $11.49 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $37.60 | N/A |
| AVG Volume (30 Days) | ★ 754.0K | 192.1K |
| Earning Date | 05-15-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.11% |
| EPS Growth | ★ 107.44 | N/A |
| EPS | ★ 0.16 | N/A |
| Revenue | ★ $541,533,000.00 | N/A |
| Revenue This Year | $9.77 | N/A |
| Revenue Next Year | $9.71 | N/A |
| P/E Ratio | $145.38 | ★ N/A |
| Revenue Growth | ★ 26.04 | N/A |
| 52 Week Low | $18.80 | $9.00 |
| 52 Week High | $27.99 | $12.12 |
Technical Indicators
Market Signals| Indicator | PCRX | CHY |
|---|---|---|
| Relative Strength Index (RSI) | 52.99 | 40.83 |
| Support Level | $20.09 | $11.46 |
| Resistance Level | $24.65 | $11.68 |
| Average True Range (ATR) | 1.11 | 0.18 |
| MACD | 0.06 | -0.06 |
| Stochastic Oscillator | 66.38 | 30.43 |
Price Performance
Historical ComparisonAbout PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
About CHY Calamos Convertible and High Income Fund
Calamos Convertible & High Income Fund is a diversified, closed-end management investment company. Its objective is to provide total return through a combination of capital appreciation and current income. The firm invests in a diversified portfolio of convertible securities and high-yield securities.